SCLX insider trading
NasdaqCM HealthcareScilex Holding Company/DE — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Scilex Holding Company/DE
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California.
Company website: www.scilexholding.com
SCLX insider activity at a glance
FilingIQ has scored 39 insider transactions for SCLX since Jan 19, 2023. The most recent filing in our index is dated Apr 17, 2026.
Across the full history, 17 open-market purchases
and 5 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SCLX insider trades is 60.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SCLX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SCLX?
- FilingIQ tracks 39 Form 4 insider transactions for SCLX (Scilex Holding Company/DE), covering filings from Jan 19, 2023 onwards. 3 of those were filed in the last 90 days.
- Are SCLX insiders net buyers or net sellers?
- Across the full Form 4 history for SCLX, 17 transactions (44%) were open-market purchases and 5 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SCLX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SCLX in?
- Scilex Holding Company/DE (SCLX) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $79.26M.
Methodology & sources
Every SCLX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.